Contact the Bench

Editorial correspondence

Peptide R Lab welcomes notes on the record behind any of its four entries: a citation quoted loosely, a newly published study on BPC-157, KLOW, KPV, or TB-500, or a regulatory update — a WADA listing change, an FDA compounding-category shift — that should be reflected on the references page. This kind of correction is the most valuable mail the notebook gets, and each is read with care.

The notes easiest to act on name the page in question, the exact passage being corrected or challenged, and a supporting source — a DOI or PubMed identifier wherever you have one — so the change can be checked against its source before anything is logged.

Editorial mailbox: notes@peptiderlab.com

Beyond the notebook's reach

So no message goes unanswered for the wrong reason: because Peptide R Lab logs and reports the literature rather than practicing medicine or selling anything, it cannot advise on or endorse human use of any compound covered here, name a dose, schedule, or route for any individual, judge whether a cited animal or cell-culture finding fits a specific person's situation, or sell, source, or help locate any compound from any supplier.

None of the four compounds is an FDA-approved medicine, and TB-500 is additionally WADA-prohibited in competitive sport. Anyone seeking guidance on an injury or condition should consult a licensed clinician. Replies aren't guaranteed and can lag; the mailbox is checked now and then.